Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Riccardo Lolatto

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|June 20, 2025
Prevalence and incidence of metabolic syndrome in people with HIV receiving cabotegravir and rilpivirineMartina Ranzenigo, Sara Diotallevi, Riccardo Lolatto, et al.
Sensors (Basel, Switzerland)|February 26, 2022
Information Retrieval from Photoplethysmographic Sensors: A Comprehensive Comparison of Practical Interpolation and Breath-Extraction Techniques at Different Sampling RatesPierluigi Reali, Riccardo Lolatto, Stefania Coelli, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 18, 2020
Investigating the Optimal Baseline Positioning to Maximize Cognitive Experimental OutcomePierluigi Reali, Riccardo Lolatto, Paola De Stefano, et al.
International Journal of Antimicrobial Agents|August 30, 2024
Improvement in high-density lipoprotein cholesterol in people with HIV who switched from a tenofovir alafenamide-containing regimen to cabotegravir plus rilpivirineCamilla Muccini, Sara Diotallevi, Riccardo Lolatto, et al.
AIDS (London, England)|September 26, 2024
CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirineCamilla Muccini, Nicola Gianotti, Riccardo Lolatto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2025
Routine HIVRNA Testing During Injectable Cabotegravir and Oral PrEP UseAngelo Roberto Raccagni, Riccardo Lolatto, Elena Bruzzesi, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Exploration of the physiological response to an online gambling task by frequency domain analysis of the electrodermal activityGiulia Rocco, Pierluigi Reali, Riccardo Lolatto, et al.
Sexually Transmitted Diseases|September 13, 2022
Sexually Transmitted Enteric Infections in Men Who Have Sex With Men Living With HIV Over 8 Years of Follow-upAngelo Roberto Raccagni, Elena Bruzzesi, Francesca Alberton, et al.
The New Microbiologica|February 28, 2023
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy?Camilla Muccini, Daniele Ceccarelli, Riccardo Lolatto, et al.
Viruses|May 25, 2024
Monkeypox Virus Neutralizing Antibodies at Six Months from Mpox Infection: Virologic Factors Associated with Poor Immunologic ResponseAngelo Roberto Raccagni, Alessandro Mancon, Sara Diotallevi, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Journal of Acquired Immune Deficiency Syndromes (1999)|June 20, 2025
Prevalence and incidence of metabolic syndrome in people with HIV receiving cabotegravir and rilpivirineMartina Ranzenigo, Sara Diotallevi, Riccardo Lolatto, et al.
Sensors (Basel, Switzerland)|February 26, 2022
Information Retrieval from Photoplethysmographic Sensors: A Comprehensive Comparison of Practical Interpolation and Breath-Extraction Techniques at Different Sampling RatesPierluigi Reali, Riccardo Lolatto, Stefania Coelli, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 18, 2020
Investigating the Optimal Baseline Positioning to Maximize Cognitive Experimental OutcomePierluigi Reali, Riccardo Lolatto, Paola De Stefano, et al.
International Journal of Antimicrobial Agents|August 30, 2024
Improvement in high-density lipoprotein cholesterol in people with HIV who switched from a tenofovir alafenamide-containing regimen to cabotegravir plus rilpivirineCamilla Muccini, Sara Diotallevi, Riccardo Lolatto, et al.
AIDS (London, England)|September 26, 2024
CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirineCamilla Muccini, Nicola Gianotti, Riccardo Lolatto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2025
Routine HIVRNA Testing During Injectable Cabotegravir and Oral PrEP UseAngelo Roberto Raccagni, Riccardo Lolatto, Elena Bruzzesi, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|October 6, 2020
Exploration of the physiological response to an online gambling task by frequency domain analysis of the electrodermal activityGiulia Rocco, Pierluigi Reali, Riccardo Lolatto, et al.
Sexually Transmitted Diseases|September 13, 2022
Sexually Transmitted Enteric Infections in Men Who Have Sex With Men Living With HIV Over 8 Years of Follow-upAngelo Roberto Raccagni, Elena Bruzzesi, Francesca Alberton, et al.
The New Microbiologica|February 28, 2023
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy?Camilla Muccini, Daniele Ceccarelli, Riccardo Lolatto, et al.
Viruses|May 25, 2024
Monkeypox Virus Neutralizing Antibodies at Six Months from Mpox Infection: Virologic Factors Associated with Poor Immunologic ResponseAngelo Roberto Raccagni, Alessandro Mancon, Sara Diotallevi, et al.
Pageof 7